SCHEMBL2646673

SCHEMBL2646673

CC(O)c1ccccc1Sc1cnc2sc(Nc3ncnc4ccccc34)nc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.38
NPC1 O15118 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KMT2A Q03164 2/20 0.37
RAB9A P51151 2/20 0.37
MAPT P10636 1/20 0.37
EGFR P00533 5/20 0.35
HTT P42858 3/20 0.35
GLA P06280 1/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 1/20 0.35
DUSP3 P51452 1/20 0.35
PTPN5 P54829 1/20 0.35
PTPN11 Q06124 1/20 0.35
MAP4K4 O95819 2/20 0.35
LTK P29376 2/20 0.35
MAPK8 P45983 2/20 0.35
LIMK1 P53667 2/20 0.35
ACVR1 Q04771 2/20 0.35
DYRK1A Q13627 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642215 0.83 NSD2 (0.39) ABCG2NPC1SMN1; SMN2KMT2AMAPT
SCHEMBL2646676 0.77 EGFR (0.37) ABCG2SMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL2642160 0.76 MET (0.39) ABCG2SMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL2642043 0.69 GCK (0.40) ABCG2NPC1SMN1; SMN2KMT2ARAB9A
SCHEMBL2642649 0.67 GCK (0.42) ABCG2NPC1SMN1; SMN2RAB9AEGFR
SCHEMBL2642250 0.67 HTT (0.43) ABCG2NPC1KMT2AMAPTEGFR
SCHEMBL2659886 0.67 GCK (0.40) NPC1SMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL2660952 0.67 PKM (0.40) NPC1SMN1; SMN2RAB9AMAPTEGFR
SCHEMBL2646674 0.66 GCK (0.39) NPC1SMN1; SMN2KMT2ARAB9AEGFR
SCHEMBL2642172 0.66 POLB (0.41) ABCG2NPC1SMN1; SMN2RAB9AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK ABCG2 383/4885NPC1 3557/4885SMN1; SMN2 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.